Wetenschappelijke publicaties

Peer-reviewed publicaties

Afsar, N. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting

Aguirre-Chang, G. et al. Post-Acute or Prolonged COVID-19 Treatment with Ivermectin for Patients with Persistent, or Post-Acute Symptoms

Aguirre-Chang, G. & A. Figueredo, COVID-19: Pre-exposure Prophylaxis with Ivermectin for exposed people.

Aguirre-Chang, G. et al. COVID-19 Persistent: Treatment with Ivermectin and Acetylsalicylic acid of patients with the persistent syndrome of anosmia or hyposmia

Babalola, O. et al. A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria

Behera, P. et al. Prophylactic role of ivermectin in SARS-CoV-2infection among healthcare workers

Beltran-Gonzalez, J. et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial.

Biber, A. et al. Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial

Budhiraja, S. et al. Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience

Bukhari, K. et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease

Cadegiani, F. A. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

Carvallo, H. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19.

Chala, R. et al. A RANDOMIZED TRIAL - INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS

Chamie-Quintero, J. et al. Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments

Cobos-Campos, R. et al. Potential use of ivermectin for the treatment and profilaxis of SARS-CoV-2 infection: Efficacy of ivermectin for SARS-CoV-2

Dias de Melo, G. Anti-COVID-19 efficacy of ivermectin in the golden hamster

Elgazzer, A. et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

Frances-Monerris, A. et al. Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent

Gorial, F.I. et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

Hashim, H.A. et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq

Hazan, S. et al. Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients

Hill, A. et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Jeffreys, L. et al. Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

Kalfas, S. et al. The Therapeutic Potential of Ivermectin for COVID-19: a systematic review of Mechanisms and Evididence.

Kerr, L. et al. Ivermectin prophylaxis used for COVID-19 reduces COVID-19 infection and mortality rates: A 220,517-subject, populational-level retrospective citywide observational study.

Kirty, R. et al. Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial

Kumar, N. et al. Moxidectin and ivermectin inhibit SARS-CoV-2 replication in VeroE6cells but not in human primary airway epithelium cells

Lawrie, T. Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance.

Merino, J. et al. Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City

Mohan, A. et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial.

Rodríguez-Gutiérrez, R. et al. Ivermectin in the Prophylaxis and Treatment of Patients with SARS-CoV-2: A Living Systematic Review and Meta-Analysis

Soto-Becarra, P. et al. Real-world effectiveness  Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Studyof hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru

Swargiary, A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies.

Tanioka, H. et al. Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?

Turkia, M. A Timeline of Ivermectin-Related Events in the COVID-19 Pandemic [April 3, 2021]

Turkia, M. FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 – A Brief Review

Wiseman, D. & P. Kory Possible clustering and/or drug switching confounding obscures up to 56% reduction of symptom persistence by ivermectin. Data Summary for comment posted to JAMA re: Lopez-Medina et al.

Gupta, D. et al. Ivermectin: potential candidate for the treatment of Covid 19. The Brazilian Journal of Infectious Diseases, 2020; vol. 24 (4): p. 369 -371

DiNicolantonia, J. et al. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart, 2020; vol. 7(4)

Pena-Silva, R. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19. British Journal of Clinical Pharmocology. 2020

Rizzo, E. Ivermectin, Antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg´s Archives of Pharmacology, 2020; July, 393 (7): p. 1153-1156.

Vora, A. et al. White paper on Ivermectin as a potential therapy for COVID-19. Indian Journal on Tuberculosis, 2020; vol. 67(3): p.448-451